Navigation Links
Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
Date:9/7/2007

- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half -

- Data Further Confirm Bavituximab's Potential to Enhance Multiple

Combination Regimens for Cancer Therapy -

ATLANTA, and TUSTIN, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported new preclinical studies showing an equivalent of its lead antibody bavituximab significantly shrank resistant human prostate tumors in mice when added to a standard regimen of androgen deprivation and docetaxel. The study findings will be presented today at the Innovative Minds in Prostate Cancer Today (IMPaCT) Conference in Atlanta by Dr. Yi Yin, a post-doctoral fellow in the laboratory of Dr. Philip Thorpe at UT Southwestern Medical Center in Dallas.

"These exciting results mimic the real life situation facing many prostate cancer patients whose disease is failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such as docetaxel," said Dr. Thorpe. "In this study of human prostate tumors in mice, we have shown that administering a bavituximab equivalent significantly enhances the tumors' response to androgen deprivation and docetaxel, with the result that these large resistant tumors shrank by an average of more than 50% over the 13-week study. These findings further strengthen the rationale for use of bavituximab as part of combination therapy regimens for the treatment of prostate cancer."

Prostate cancer is the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 1, 2011 Reportlinker.com announces that a new market ... Pen Injectors http://www.reportlinker.com/p0369406/Pen-Injectors.html ... increasing number of drugs in pre-filled disposable cartridges and ... the expense of other drug delivery methods such as ...
... Feb. 1, 2011 Reportlinker.com announces that a ... catalogue: Epoetin alfa - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
Cached Medicine Technology:Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
(Date:6/18/2013)... Alabama (PRWEB) June 19, 2013 Consumer ... and two other law firms have launched a new ... injuries caused by dialysis. The website is http://www.DialysisLawsuitAttorneys.com ... was time to begin offering legal services to people ... drugs GranuFlo and NaturaLyte, or who may have suffered ...
(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...
(Date:6/18/2013)... As a sponsor of the 2013 Fourth of July ... Lake Meridian Chiropractic want you to get out and celebrate! ... event and are excited to be involved. “My husband and I ... loved going to the Kent Splash event. It's a tradition that ... to financially support this fun day.” , The 2013 ...
(Date:6/18/2013)... IL (PRWEB) June 18, 2013 Exposed Skin ... helping thousands of acne suffers of all ages finally achieve ... other acne treatment products, this new acne clearing system combines ... acne, and prevent new acne from forming. , ... ExposedSkinCareReview.org believes these products are some of the most effective ...
(Date:6/18/2013)... (PRWEB) June 19, 2013 "What if ... a day could boost your health and well-being? Well, ... founder of Sublime Beauty®. "It is called Skin ... centuries but became a lost art. Now, people are ... about Skin Brushing, and so do certain health conscious ...
Breaking Medicine News(10 mins):Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2
... 9 Family Research Council President Tony Perkins made the ... joint session of Congress. , , ... Tomorrow night in a live webcast at frcaction.org, ... Perkins will be joined by Senator Jim DeMint (R-SC), House ...
... , , , ... no meaningful health care reform , , ... Congress Wednesday evening, USAction President William McNary called on Congress to ... companies - and pass quality, affordable health care reform with a ...
... now, the mode of action of nitrogen-containing bisphosphonate (N-BP) ... prevent skeletal complications in bone metastasis, has been almost ... journal Genome Biology have used ,barcoded, yeast ... cellular response to N-BPs, opening up opportunities for the ...
... a 24/7 video and audio studio with fiber optic and radio ISDN ... following is being issued by Vanderbilt: , , ... Development , Turner, an expert on mental health policy and family ... as a Robert Wood Johnson Senior Health Policy Fellow. , ...
... A Center for Public Accountability report submitted today to state Attorney ... Treatment Center , , LOS ANGELES, Sept. ... office of Attorney General Jerry Brown today providing evidence that executives ... diversion of, up to $22 million in assets that could been ...
... , , , , ... DVA ), a leading provider of kidney care services for those ... offering individualized treatment options based on optimal patient care standards and ... , Victor Tlatelpa, 16, is not your everyday ...
Cached Medicine News:Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2Health News:Vanderbilt Experts For Health Care Debate 2Health News:SEIU Local 721 Calls for Attorney General to Investigate Self-Dealing and $22 Million in Extra Costs at Tarzana Treatment Center 2Health News:DaVita's Patient-Centric Modalities Offer Students with Kidney Disease More Choices 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: